You are here

İmmünglobulinler ve Septisemi

Immunglobulins and Septicemia

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Due to placental type of ruminants and equines, immunoglobulins cannot pass through from mother to newborn and immunity of these animals are provided with colostrum. Failure of passive transfer occurs in ani-mals that cannot receive colostrum in first 48 hours and this situation causes catching an infection easily in neo-nate. The most common diseases that occur due to failure of passive transfer are septicemic diseases. In order to prevent septicemic diseases, antimicrobial therapy and supportive therapy are used today. As a result of scientific research in recent years, it was reported that immunoglobulins are used in support therapy of septicemic disease. Our purpose in this review are to evaluate the published studies on septicemia and immunoglobulins in the light of present scientific knowledge and in accordance with these evaluations, inform scientists, private veterinarians and breeders about the use of immunoglobulins in veterinary.
Abstract (Original Language): 
İmmünglobulinler geviş getiren ve tek tırnaklı hayvanlardaki plasenta tipi nedeniyle anneden yavruya geçememekte ve bu hayvanların bağışıklığı doğumu takiben alınan kolostrum sütü ile sağlanmaktadır. İlk 48 saat içinde yeterli miktarda kolostrum alamamış hayvanlarda pasif transfer yetmezliği sendromunun ortaya çıkmakta ve bu durum yavruların kolayca enfeksiyona yakalanmasına yol açmaktadır. Pasif transfer yetmezliği sebebiyle ortaya çıkan hastalıkların başında septisemik hastalıklar gelmektedir. Septisemik hastalıkların önüne geçmek için günümüzde antimikrobiyal tedavi ve destek tedavileri uygulanmaktadır. Son yıllardaki bilimsel araştırmalar neticesinde immünglobulinlerin septisemik hastalıklarda uygulanan destek tedavisinde kullanıldığı bildirilmiştir. Bu derlemedeki temel amacımız güncel bilimsel bilgiler ışığında immünglobulinler ve septisemi konularında dünya çapında yapılmış bulunan çalışmaları değerlendirmek ve bu değerlendirmeler doğrultusunda immünglobu-linlerin veteriner hekimlikteki kullanımı hakkında bilim insanlarını, sahadaki veteriner hekimleri ve yetiştiricileri bilgilendirmektir.

REFERENCES

References: 

1. Akşit, F., Akgün, Y., Kiraz, N., 1996. Mikrobiyo-loji. Anadolu Üniversitesi Yayınları, Eskişehir.
2. Alanoğlu, G., 2007. Özgün olmayan immünglo-bulin kullanımı. Türk Hematoloji Derneği Hema-tolojide Destek Tedaviler Kursu, 15-17 Kasım, Erzurum. http://www.thd.org.tr/thdData/userfiles/file/HEM_DES_2007_1.pdf. Erişim Tarihi: 10.04.2013.
3. Altıntaş, A., Kantarcı, O., Siva, A., 1996. Oto-immun nörolojik hastalıklarda tedavi stratejileri. Türk Nöroloji Dergisi, 2 (3-4), 70-78.
4. Anonim, 2005. Kuduz korunma ve kontrol yö-nergesi. http://www.saglik.gov.tr/TR/dosya/1-75996/h/kuduz-korunma-ve-kontrol-yon.... Erişim Tarihi: 10.04.2013.
5. Anonim, 2007. İdiyopatik trombositopenik pur-pura. Uludağ Üniversitesi Sağlık Kuruluşları ÇSH Anabilim Dalı. http://sakur.uludag.edu.tr/dosya/FR-HYE-04-416-02.pdf. Erişim Tarihi: 10.04.2013).
6. Arısoy, E.S., 2010. Yenidoğan sepsisi: Tanı ve tedavi yaklaşımları. Ankem Dergisi, 24 (2), 168-175.
7. Aydoğdu, B., Yurtçu, M., Akbulut, S., Gürbilek, M., Toy, H., Günel, E., 2008. Deneysel nekroti-zan enterokolit modelinde ağız yolu ile verilen immünglobülin A’nın etkisi. Çocuk Cerrahisi Dergisi, 22 (1), 8-14.
8. Balan, P., Han, K.S., Rutherfurd-Markwick, K., Singh, H., Moughan, P.J., 2010. Immunomodula-tory effects of ovine serum immunoglobulin in the growing rat. Animal, 4(10), 1702-1708.
40
9. Basoglu, A., Camkerten, I., Serving, M., 1999. Serum immunoglobulin concentrations in diarr-heic calves and their measurement single radial immunodiffusion. Israel Journal of Veterinary Medicine, 54 (1), 9-10.
10.Behre, G., Schedel, I., Nentwig, B., Wörmann, B., Essink, M., Hiddemann, W., 1992. Endotoxin concentration in neutropenic patients with sus-pected gram-negative sepsis: correlation with cli-nical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immu-noglobulins. Antimicrobial Agents and Chemot-herapy, 36 (10), 2139-2146.
11.Berlot, G., Bacer, B., Piva, M., Lucangelo, U., Viviani, M., 2007. Immunoglobulins in sepsis. Advances In Sepsis, 6 (2), 41-46.
12.Bianco, D., Armstrong, J., Washabau, R., 2007. Threatment of severe immune-mediated throm-bocytopenia with human IV immunoglobulin in 5 dogs. Journal of Veterinary Internal Medicine, 21 (4), 694-699.
13.Boros, P., Gondolesi, G., Bromberg, J.S., 2005. High dose intravenous immunoglobulin treat-ment: mechanisms of action. Liver Transplanta-tion, 11 (12), 1469-1480.
14.Breedveld, F., 2000. Therapeutic monoclonal antibodies. Lancet, 355, 735-740.
15.Bruton, O.C., 1952. Agammaglobulinemia. Pedi-atrics, 9 (6), 722-728.
16.Byrne, K.P., Giger, U., 2002. Use of human im-munoglobulin for threatment of severe erythema multiforme in a cat. Journal of the American Ve-terinary Medical Association, 220 (2), 197-201.
17. Camcıoğlu, Y., Aytaç, E., 2007. Sepsisin immü-nopatogenezisi. Türk Yoğun Bakım Dergisi, 5, 81-85.
18. Camcıoğlu, Y., 2009. İmmunglobulin tedavisi. Journal of Pediatric Infection, 3, 69-74.
19.Cohn, E.J., Luetscher, J.A., Oncley, J.L., Armst-rong Jr, S.H., Davis, B.D., 1940. Preparation and properties of serum and plasma proteins. III. Size and charge of proteins separating upon equilibra-tion across membranes with ethanol-water mixtu-res of controlled pH, ionic strength and tempera-ture. Journal of the American Chemical Society, 62 (12), 3396-3400.
20.Craft, J.M., Watterson, D.M., Van Eldik, L.J., (2005). Neuroinflammation: a potential therapeu-tic target. Expert Opinion on Therapeutic Tar-gets, 9, 887-900.
21. Çakıroğlu, D., Meral, Y., Pekmezci, D., Onuk, E.E., Gökalp, G., 2010. Yeni doğan buzağılarda çeşitli hematolojik ve biyokimyasal parametreler ile kolostral immun globulinler arasındaki ilişki-nin belirlenmesi. Fırat Üniversitesi Sağlık Bilim-leri Veteriner Dergisi, 24 (1), 43-46.
22. Çitil, M., Karapehlivan, M., Güneş, V., Atakişi, E., Uzlu, E., 2004. Septisemi şüpheli buzağılarda serum sialik asit ve bazı biyokimyasal parametre düzeyleri. Kafkas Üniversitesi Veteriner Fakülte-si Dergisi, 10 (1), 19-22.
23.Deymeer, F., 2005. Myasthenia Gravis'te tedavi. Türkiye Klinikleri Dahili Tıp Bilimleri Dergisi, 1 (22), 38-43.
24.Diker, K.S., (2005). İmmunoloji. Medisan Yayın-ları, Ankara.
25. Esen, F., Senturk, E., Ozcan, P.E., Ahishali, B., Arican, N., Orhan, N., Ekizoğlu, O., Ustek, D., Kucuk, M., Kaya, M., 2012. Intravenous immu-noglobulins prevent the breakdown of the blood-brain barrier in experimentally induced sepsis. Critical Care Medicine, 40 (4), 1214-1220.
26. Francisco, S.A., Quigley III, J.D., 1993. Serum immunoglobulin concentrations after feeding ma-ternal colostrum or maternal colostrum plus co-lostral supplement to dairy calves. American Jo-urnal of Veterinary Research, 54 (7), 1051-1054.
27.Gasque, P., Fontaine, M., Morgan, B.P., 1995. Complement expression in human brain. Bi-osynthesis of terminal pathway components and regulators in human glial cells and cell lines. The Journal of Immunology, 154 (9), 4726-4733.
28.Gelfand, E.W., 2012. Intravenous immune globu-lin in autoimmune and inflammatory diseases. New England Journal of Medicine, 367 (21), 2015-2025.
29.Gomez, S.M., Morris, D.O., Rosenbaum, M.R, Goldschmidt, M.H., 2004. Outcome and compli-cations associated with treatment of pemphigus foliaceus in dogs: 43 cases (1994-2000). Journal of the American Veterinary Medical Association, 224 (8), 1312-1316.
30.Hammer, C., Tyler, H., Roth, J.A., Quigley III, J.D., 2004. Characterization of reactions to intra-venous immunoglobulin in neonatal calves. Ani-mal Industry Report, 650 (1), 66.
31.Hamrock, D.J., 2006. Adverse events associated with intravenous immunoglobulin therapy. Inter-national Immunopharmacology, 6 (4), 535-542.
32. Imbach, P., Barandun, S., d’Apuzzo, V., Baum-gartner, C., Hirt, A., Morell, A., Rossi, E., Schoni, M., Vest, M., Wagner, H.P., 1981. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet, 317 (8232), 1228-1231.
33. Jacob, A., Hensley, L.K., Safratowich, B.D., Quigg, R.J., Alexander, J.J., 2007. The role of complement cascade in endotoxin-induced septic encephalopathy. Laboratory Investigation, 87 (12), 1186-1194.
34. Jenson, H.B., Pollock, B.H., 1998. The role of intravenous immunoglobulin for the prevention
41
and treatment of neonatal sepsis. Seminars in Pe-rinatology, 22 (1), 50-63.
35. İnce, E., 2011. Sepsis ve septik şok tedavisi. Journal of Pediatric Infection, 5 (1), 106-118.
36.Karadal, A.E., 2009. SIRS ve sepsis hastalarında deksmedetomidin ve propofolün immün sistem üzerine etkileri. Uzmanlık Tezi, Çukurova Üni-versitesi Tıp Fakültesi Anestezi ve Reanimasyon Anabilim Dalı, Adana.
37. Kav, K., Erganiş, O., 2008. Balıklarda bağışıklık sistemi. Eurasian Journal of Veterinary Sciences, 24 (1), 97-106.
38. Keleş, İ., Ceylan, C., Erbaş, O., 2012. Çocukta sıra dışı penil travma: Köpek ısırması olgusu. Sa-karya Medical Journal, 2 (2), 99-101.
39.Kellerman, D.L., Bruyette, D.S., 1997. Intrave-nous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs. Journal of Veterinary Internal Medicine, 11 (6), 327-332.
40. Kılıç, S.Ş., (2003). İmmun yetmezlikli hastalarda intravenöz immünglobulin tedavisi. Güncel Pedi-atri, 1, 92-95.
41. Kırış, S., 1990. İntravenöz immünglobulin prepa-ratlarının yapısal ve işlevsel özellikleri. Ankem Dergisi, 4 (3), 390-400.
42.Koffman, B.M., Dalakas, M.C., 1997. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpo-pulations: Assessments based on controlled tre-atment trials in patients with neurological disea-ses. Muscle & Nevre, 20 (9), 1102-1107.
43.Kol, A., 2008. Human intravenous immunoglo-bulin (IVIG) therapy in veterinary medicine - A review. Israel Journal of Veterinary Medicine, 63 (1), 23-27.
44. Kreymann KG, de Heer G, Nierhaus A, Kluge S (2007). Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Cri-tical Care Medicine, 35 (12), 2677-2685.
45.Kulkarni, A.P., Kellaway, L.A., Lahiri, D.K., Kotwal, G.J., 2004. Neuroprotection from comp-lement-mediated inflammatory damage. Annals of the New York Academy of Sciences, 1035 (1), 147-164.
46. Lemieux, R., Bazin, R., Néron, S., 2005. Thera-peutic intravenous immunoglobulins. Molecular Immunology, 42 (7), 839-848.
47. Losonsky, G.A., Johnson, J.P., Winkelstein, J.A., Yolken, R.H., 1985. Oral administration of hu-man serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacoki-netic and functional analysis. Journal of Clinical Investigation, 76 (6), 2362-2367.
48.Mueller, R.S., Krebs, I., Power, H.T., Fieseler, K.V., 2006. Pemphigus foliaceus in 91 dogs. Jo-
urnal of the American Animal Hospital Associa-tion, 42 (3), 189-196.
49.Norby-Teglund, A., Haque, K.N., Hammarström, L. 2006. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological ae-tiology and severity of sepsis. Journal of Internal Medicine, 260 (6), 509-516.
50.Nutall, T.J., Malham, T., 2004. Successful intra-venous human immunoglobulin threatment of drug-induced Stevens-Johnson syndrome in a dog. Journal of Small Animal Practice, 45 (7), 357-361.
51.Oesser, S., Schulze, C., Seifert, J., 1999. Protec-tive capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia. Research in Experimental Medicine, 198 (6), 325-339.
52. Oflazoğlu, B., Öztürk, F., Açık, H.K., Öncel, Ç., Anadol, Ü., Forta, H., 2006. Nörolojik hastalık-larda IV immünglobulin tedavisinin yan etkileri. Türk Nöroloji Dergisi, 12 (1), 21-24.
53. Öneş, Ü., 1990. İntravenöz immünglobulinlerin klinik uygulamaları. Ankem Dergisi, 4 (3), 401-406.
54.Rahilly, K.J., Keating, J.H., O’Toole, T.E., 2006. The use of intravenous human immunoglubulin in threatment of severe pempohigus foliaceus in a dog. Journal of Veterinary Internal Medicine, 20 (6), 1483-1486.
55. Schedel, I., Dreichhausen, U., 1995. The therapy of gram-negative septicotoxic diseases with pen-taglobin, an immunoglobulin with an elevated IgM content (a prospective, randomized clinical study). Anesteziologiia i Reanimatologiia, 199, 4-9.
56. Schwartz, S.A., 1990. Intravenous immunoglobu-lin (IVIG) for the therapy of autoimmune disor-ders. Journal of Clinical Immunology, 10 (2), 81-89.
57. Schwartz, S.A., 2000. Intravenous immunoglobu-lin treatment of immunodeficiency disorders. Pe-diatric Clinics of North America, 47 (6), 1355-1369.
58. Scott-Moncrieff, J.C., Snyder, P.W., Reagan, W.J., Glickman, L.T., 1997. Intravenous admi-nistration of human immune globulin in dogs with immune-mediated hemolytic anemia. Jour-nal of the American Veterinary Medical Associa-tion, 210 (11), 1623-1627.
59. Şentürk, E., Esen, F., 2012. Sepsiste immunoglo-bülin tedavisi ile kompleman inhibisyonu ve nö-roproteksiyon. Türk Anesteziyoloji ve Reanimas-yon Derneği Dergisi, 40 (4), 184-192.
60. Tel. N., Öner, Ü., Paşaoğlu, Ö., 1991. Patoloji. Anadolu Üniversitesi Yayınları, Eskişehir.
42
61. Thampakkul, S., Ballow, M., 2001. Replacement intravenous immune serum globulin therapy in patients with antibody immune deficiency. Im-munology and Allergy Clinics of North America, 21 (1), 165-184.
62. Toprak, D., Soysal, A., Türel, Ö., Bakır, M., 2007. Rotavirüs ishalinde oral immunoglobulin tedavisi: İki olgu sunumu. Çocuk Enfeksiyon Dergisi, 1, 115-117.
63. Trotman, T.K., Philips, H., Fordyce, H., King, L.G., Morris, D.O., Giger, U., 2006. Threatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs. Journal of the American Animal Hospital Asso-ciation, 42 (4), 312-320.
64. Tuncer, E., Kılıç, Ş., 2006. Yenidoğanın immün sistemi. Güncel Pediatri, 3, 92-95.
65. van Engelen, B.G., Miller, D.J., Pavelko, K.D., Hommes, O.R., Rodrigues, M., 1994. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple screlosis. Journal of Neurology, Neuro-surgery, and Psychiatry, 57, 65-68.
66. von Behring, E., Kitasato, S., 1890. Ueber das zustandekommen der diphtherie-immunitgt und der tetanus-immunitzt bei thieren. Deutscbe Me-dizhiscbe Wocbenschift, 16, 1113-1114.
67.Werdan, K., 2001. Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. Therapeutic Ap-heresis and Dialysis, 5 (2), 115-122.
68.Whelan, M.F., O'Toole, T.E., Chan, D.L., Ro-zanski, E.A., DeLaforcade, A.M., Crawford, S.L., Cotter, S.M., 2009. Use of human immunoglobu-lin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated he-molytic anemia. Journal of Veterinary Emer-gency and Critical Care, 19 (2), 158-164.
69.Wolach, B., 1997. Neonatal sepsis: Pathogenesis and supportive therapy. Seminars in Perinato-logy, 21 (1), 28-38.
70. Yıldızdaş, D., Yapıcıoğlu, H., Tümgör, G., Er-bey, F., 2005. Çocuk yoğun bakım ünitesi'nde sepsis nedeni ile izlenen hastalarda poliklonal int-ravenöz immünglobülin tedavisi mortaliteyi azal-tıyor mu. Çocuk Sağlığı ve Hastalıkları Dergisi, 48, 136-141.
71. Ziegler, E.J., McCutchan, J.A., Fierer, J., Glau-ser, M.P., Sadoff, J.C., Douglas, H., Braude, A.I., 1982. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medi-cine, 307 (20), 1225-1230.

Thank you for copying data from http://www.arastirmax.com